Logo image
Sign in
Back
Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis
Journal article   Peer reviewed

Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis

Alhassane Diallo, Miguel Carlos-Bolumbu and Florence Galtier
Acta Diabetologica, Vol.60(12), pp.1651-1662
13/07/2023
DOI: https://doi.org/10.1007/s00592-023-02154-4
PMID: 37439858

Abstract

Blood pressure CVOTs GLP-1 RAs MACE Meta-analysis SGLT2i Humans Diabetes Mellitus, Type 2 Renal Insufficiency Hypoglycemic Agents Sodium-Glucose Transporter 2 Inhibitors Glucagon-Like Peptide-1 Receptor Blood Pressure Cardiovascular Diseases Heart Failure Myocardial Infarction Glucagon-Like Peptide 1 Stroke
To investigate the lowering BP effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on the risk of major cardiovascular event stratified by glucose-lowering drugs, baseline BP, glycated hemoglobin (HbA1c), and history of cardiovascular disease in patients with type 2 diabetes.
url
Find in HALView

Metrics

1 Record Views

Details

Logo image